Abstract:Clinical trials of investigational agents in systemic lupus erythematosus (SLE) have focused on targeting dysregulated B and T cells; however, recent translational research findings of the importance of the dysregulation of the innate immune system in SLE have led to clinical trials that target interferon. Three biologics that target type I interferons have been tested for their efficacy and safety in active SLE patients; these phase II trials have tested the hypothesis that down-regulation of interferon-regulated gene expression (the interferon signature) lessen the clinical burden of SLE. Rontalizumab, an anti-interferon-α monoclonal antibody, was studied in patients who had discontinued immunosuppressants. This study failed to show efficacy as assessed by both two outcome assessments; however, in low interferon signature patients, response was higher and corticosteroid usage was less in rontalizumab-treated patients. Sifalimumab, another anti-interferon-α monoclonal antibody, was studied in patients who remained on standard of care therapy. This study showed significantly better efficacy in patients treated with two sifalimumab dosages; significant differences were seen in the high interferon signature group. In a similar design and in a similar population as the sifalimumab study, anifrolumab, a monoclonal antibody that binds to a type I interferon receptor, was studied in patients who remained on standard of care therapy. In this study, one dosage group demonstrated efficacy and statistically significant effects were achieved in both tested dosage groups with secondary end points. Oral corticosteroid reduction to ≤7.5 mg daily was achieved in one of the tested dosage groups and organ-specific outcomes were significantly improved in that same group. For all studies, no significant differences in serious adverse effects were seen; although, herpes zoster infections were increased in sifalimumab- and anifrolumab-treated patients and influenza rates were increased in anifrolumab-treated patients. Anifrolumab is currently in pivotal phase III studies. Data appear to support the concept that targeting type I interferon in SLE patients associates with clinical efficacy and safety. Further data are forthcoming from ongoing phase III clinical trials of anifrolumab. Other drug development efforts should be considered that target plasmacytoid dendritic cells and toll like receptors given the effects these components have on interferon production.

Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention

Anti-TNF therapy in patients with HBV infection—analysis of 87 patients with inflammatory arthritis

Rheumatoid arthritis induced by alpha-interferon therapy

Viruses and arthritis: new challenges in diagnosis, therapy, and immunization

Interferons and autoimmune disorders

Interferon Therapy for HCV-Associated Glomerulonephritis: Meta-Analysis of Controlled Trials

[Progress in interferon: A treatment of Behcet syndrome]

Interferon-α As Maintenance Therapy Can Significantly Reduce Relapse in Patients with Favorable-Risk Acute Myeloid Leukemia

A Guide to the Use of Interferon-Alpha in the Management of Chronic Myelogenous Leukaemia

Clinical Pharmacokinetics of Interferons

Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?

Azathioprine therapy induces selective NK cell depletion and IFN-γ deficiency predisposing to herpesvirus reactivation

Autoantibodies and Anti-Interferon Antibody in Patients with Chronic Viral Hepatitis and Its Clinical Significance: a Preliminary Investigation.

Clinical characteristics and treatment outcomes of acute severe autoimmune hepatitis

New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors

Exogenous IFN-beta regulates the RANKL-c-Fos-IFN-beta signaling pathway in the collagen antibody-induced arthritis model

S4358 Infliximab-Induced Autoimmune Hepatitis Progressing to Acute Liver Failure in a Patient With Ankylosing Spondylitis and Rheumatoid Arthritis

Longitudinal Analysis Over Decades Reveals the Development and Immune Implications of Type I Interferon Autoantibodies in an Aging Population

Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Interferon

Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis